Trial Profile
Target-ABC (Targeted AntiBiotics for Chronic pulmonary disease): Can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis and asthma
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Ciprofloxacin (Primary) ; Piperacillin/tazobactam (Primary)
- Indications Chronic obstructive pulmonary disease; Pseudomonal infections; Respiratory tract infections
- Focus Therapeutic Use
- Acronyms Target-ABC
- 30 Mar 2023 Status changed from recruiting to discontinued.
- 20 Dec 2016 New trial record